Hartaj Singh

Moderna Inc (NASDAQ: MRNA) is back in focus as it is making advancements in cancer treatment. Moderna is likely to become a “five-product commercial company” by 2026, according to Oppenheimer. The Moderna Analyst: Hartaj Singh upgraded the rating for Moderna to Outperform, while raising...

Moderna Inc (NASDAQ: MRNA) shares are experiencing weakness for a second straight session following the release of its quarterly results. The Moderna Analyst: Oppenheimer analyst Hartaj Singh downgraded Moderna shares from Outperform to Perform. The Moderna Thesis: Moderna exceeded...

Shares of coronavirus vaccine developer Inovio Pharmaceuticals Inc (NASDAQ: INO) were surging Friday after a vote of confidence from the Street.  Bullish Analyst, Fund Stake Prop Up Stock: Oppenheimer analyst Hartaj Singh initiated coverage of Inovio shares with an Outperform rating and...

Coronavirus vaccine developer Moderna Inc (NASDAQ: MRNA) has impressed Wall Street analysts with its comprehensive approach and forward thinking. The Moderna Analyst: Oppenheimer analyst Hartaj Singh maintained an Outperform rating and $108 price target. The Moderna Thesis: Moderna'...

Moderna Inc (NASDAQ: MRNA) shares were trading at new highs Monday following the release of positive interim Phase 1 immunogenicity and safety data for its mRNA-1273 coronavirus vaccine candidate.  The Moderna Analysts Goldman Sachs analyst Salveen Richter maintained a Buy rating on Moderna...

ArQule, Inc. (NASDAQ: ARQL) shares are up 367 percent year-over-year, but they’re still undervalued, according to Oppenheimer. The Rating Analyst Hartaj Singh initiated coverage on ArQule with an Outperform rating and $7 price target. The Thesis Oppenheimer expects the ARQ 092/751 and ARQ...

Alexion Pharmaceuticals, Inc. (NASDAQ: ALXN) will report fourth-quarter earnings in late January, according to Oppenheimer.  The Analyst Oppenheimer's Hartaj Singh maintains an Outperform on Alexion Pharmaceuticals with a $115 price target.  The Thesis Alexion...

Sarepta Therapeutics Inc (NASDAQ: SRPT), a smid-cap biopharmaceutical company that focuses on the treatment of rare neuromuscular diseases including Duchenne muscular dystrophy, saw its stock peak north of $60 per share in late 2016 after the U.S. Food and Drug Administration green-lighted its DMD...

Sarepta Therapeutics Inc (NASDAQ: SRPT) was trading higher Friday after a Thursday-night update of Exondys 51 annual sales guidance from $80 million to $95 million. The figure still fell short of Oppenheimer’s $100 million estimate — and analyst Hartaj Singh even considers his rate...

Shares of Sarepta Therapeutics Inc (NASDAQ: SRPT) have declined sharply, with continued concerns around reimbursement and competition. The shares could appreciate going ahead, driven by “the ongoing eteplirsen EU application review process and increasing visibility on a successful US launch,...

BTIG's Hartaj Singh downgrades Epirus Biophramaceuticals Inc (NASDAQ: EPRS) from Buy to Neutral. Share were recently down about 18 percent at $0.88. Epirus made senior management changes Tuesday, as well as a change in strategy moving forward in the fiscal year. CEO Amit Munshi stepped down...

The M&A rumors continue to swirl around biotech firm Medivation Inc (NASDAQ: MDVN), and a SunTrust analyst has commented that the latest take-over chatter highlights the value of the company. A Bloomberg report said Medivation has rejected a take-out offer from Sanofi SA (ADR) (NYSE: SNY),...